In the case of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), they have demonstrated significant reductions in major adverse cardiovascular event (MACE) endpoints, with the observed effects especially strong for reducing ischaemic events related to ASCVD [9]. This evidence concerns the gene GCG and atherosclerosis.